Labatec Pharma announces exclusive licensing agreement signed with Radius Health Inc., to commercialise Tymlos in Switzerland and the Middle East North Africa region

LABATEC PHARMA ANNOUNCES EXCLUSIVE LICENSING AGREEMENT
SIGNED WITH RADIUS HEALTH INC, TO COMMERCIALISE TYMLOS
IN SWITZERLAND AND THE MIDDLE EAST NORTH AFRICA REGION

 

Geneva, June 9, 2022 – Labatec Pharma SA (Labatec) signed a new licensing agreement with Radius Health, Inc. (Radius) (NASDAQ: RDUS), for the rights to commercialise TYMLOS® (abaloparatide), a subcutaneous injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

In accordance with the terms of the agreement, Labatec will register, commercialize, and distribute TYMLOS on an exclusive basis in Switzerland and the Middle East North Africa (MENA) region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco. The responsibilities include all commercial activities related to TYMLOS including sales, marketing, medical affairs, pricing, and reimbursement. Radius will be responsible for supplying the drug to Labatec.

Faisal Darwazeh, CEO of Labatec: “We are pleased to enter in a partnership with Radius, to bring an alternative and innovative treatment for osteoporosis to our patients in Switzerland and the MENA region, building on our existing and growing portfolio of licensed and innovative medicines. We are looking forward to this collaboration.”

Chhaya Shah, Senior Vice President of Radius (leader of the clinical and regulatory activity for abaloparatide): “We are delighted to partner with Labatec in these very important countries and to make TYMLOS available to patients who suffer from osteoporosis.”

About Labatec

A Swiss based privately owned pharmaceutical company, based in Meyrin (Geneva). Labatec develops and markets medicines that contribute to improving patients’ quality of life. Labatec is a leading licensing partner in the specialty and innovative medicines segments, across the Swiss and MENA markets.

Labatec’s extensive portfolio includes more than 70 high-quality products, manufactured in Europe and Canada, and supplied to 14 countries comprising Switzerland, Austria, the Middle East and North Africa. Labatec is a recognized partner of choice for hospitals (anti-infectious, anesthetic, antiemetic and oncological products) and has an established retail presence in the therapeutic categories of osteoporosis, muscle relaxants, women’s health and opthamology.

http://www.labatecpharma.com/

For further information please contact:
Labatec Pharma SA
Business Development Team
Email: bd@labatec.com
Tel: +41 22 785 95 00 (Head Office)

For media enquiries please contact:
Labatec Pharma SA
Head of Press & Communications
Email: press@labatec.com
Tel: +41 22 785 95 00 (Head Office)

About Radius

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.

TYMLOS (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies.

For further information please contact:
Investor & Media Relations
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017

14 June 2022

News

«

Labatec Pharma SA announces Exclusive Licensing Agreement signed with Futura Medical to Commercialise MED3000 in the Gulf and Middle East Region

Labatec Pharma SA (Labatec) has signed an exclusive licensing agreement with Futura Medical plc (AIM: FUM) (Futura), for the rights to commercialise the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment MED3000.

Under the terms of the agreement, which is for an initial 8-year period, Futura and Labatec will work together to gain marketing authorisation and commercialise MED3000 as a clinically proven treatment for Erectile Dysfunction in Jordan, Lebanon, Iraq and the GCC region of Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman and Bahrain.

Faisal Darwazeh, CEO of Labatec: “We are delighted to license Futura’s MED3000 for the GCC and other Middle Eastern countries. There is significant market potential in the region for MED3000 as a trusted, branded medicine for enhancing erectile performance. We are confident of generating significant value and long-term sustainable growth for both Futura and Labatec with this innovative, clinically proven product.”

James Barder, Chief Executive of Futura Medical: “This is our third commercial agreement for MED3000, and we are excited to be working with Labatec to expand the product’s market reach into Middle Eastern countries as we continue MED3000’s regulatory and commercial rollout worldwide. Labatec is a trusted medicines supplier in the region that is ideally placed to market both prescription and retail products, and its local teams have a deep understanding of regional markets and experience in rapidly registering and launching new products. We look forward to working closely with them.”

About Labatec

Labatec is a Swiss-based private pharmaceutical company, headquartered in Geneva, Switzerland. Our company has 50+ years experience in the production and supply of medicines to 11 countries comprising Switzerland, the Middle East and North Africa and expanding today in Europe. We aim to be a leading licensing partner in generic and specialty innovative medicines in our markets with an extensive portfolio of 70+ products in both the retail and hospital segments. We serve our communities by developing, manufacturing, and distributing high quality medicines covering major therapeutic areas such as musculo-skeletal, ophthalmology, anaesthetics, oncology, anti-infectives and women’s health.
Labatec Pharma is a privately owned business, founded in 1957 and acquired in 2008 by Dr. Samih Darwazah, founder of Hikma Pharmaceuticals PLC. www.labatecpharma.com

For further information please contact:
Labatec Pharma SA
Viktoria Stepanova, COO
Email: bd@labatec.com
Tel: +41 22 785 95 00 (Head Office)

For media enquiries please contact:
Labatec Pharma SA
Head of Press & Communications
Email: press@labatec.com
Tel: +41 22 785 95 00 (Head Office)

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura’s topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. MED3000 begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000

For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 922 0900
Full press release here:
https://polaris.brighterir.com/public/futura_medical/news/rns/story/rmnez9w

29 September 2021

News

« »

LABATEC Women Health and Mithra announce the successful launch of Myloop® in Switzerland

LABATEC WOMEN HEALTH AND MITHRA ANNOUNCE THE SUCCESSFUL LAUNCH OF MYLOOP® IN SWITZERLAND

A hormonal contraceptive ring

 

Geneva, 10th of June 2021 – LABATEC successfully launches a contraceptive vaginal ring – MyLoop® manufactured by our partner Mithra.

About MyLoop®

This contraceptive vaginal ring is a generic of NuvaRing®. This medicine will be marketed as MyLoop®, in the form of a vaginal ring containing 11.7mg of Etonogestrel and 2.7mg of Ethinylestradiol. This generic has a shelf-life of 36 months can be stored at room temperature.

About Labatec

A Swiss based privately owned pharmaceutical company, based in Meyrin (Geneva) since 1957, Labatec develops and markets medicines that contribute to improve patients quality of life. Our portfolio includes more than 60 high quality products, manufactured in Europe and Canada. Labatec is a recognized partner choice for Swiss hospitals (anti-infectious, anaesthetic, antiemetic and oncological products) and has an established retail presence in the therapeutic categories of osteoporosis, muscle relaxants and women’s health. In the women’s health segment, our strategy is to offer a wide range of contraceptives at affordable prices for patients.
For more information, please visit http://www.labatecpharma.com/

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. Mithra explores the potential of Estetrol, a unique native oestrogen in a wide range of applications in women’s health and beyond (covid-19, neuroprotection,…). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Contact for more information
myloop@labatec.com
Labatec Pharma SA, 1217 Meyrin (GE)

9 June 2021

News

« »

Get in touch

Would you like to discuss a collaboration or partnership project? Get in touch with us at partnering@labatec.com or connect with us at one of the upcoming events.

For other enquiries, please visit our contact page.